Get started
Author

Alejandro León Garrido-Lecca

Observed names: Alejandro Leon, Alejandro Leon Garrido-Lecca, León Garrido Lecca, Alejandro
ORCID: 0009-0007-7137-0083
Observed ORCID: 0009-0007-7137-0083
OpenAlex ID: A5032328337
Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis
2024 · Rodrigo Motta-Guerrero, Alejandro Leon Garrido-Lecca, et al. · Frontiers in Oncology · 9
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports
2023 · Victor M Rivera-Francia, Virgilio E. Failoc-Rojas, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
Early cancer detection: Analysis of a comprehensive screening program in a private clinic in Peru
2025 · Alejandro Leon Garrido-Lecca, Roberto E. Alvarado-Cordova, et al. · Journal of Public Health Research · 1
Clinical and laboratory characteristics and management in patients diagnosed with multiple myeloma: real-world cohort in a Peruvian referral clinic
2026 · Victor Rivera Francia, Alejandro Leon Garrido-Lecca, et al. · ecancermedicalscience
PDF
Associated factors for poor response in advanced EGFR-mutated NSCLC patients under tirosine kinasa inhibitors: Peruvian real-world data.
2021 · Rodrigo Motta Guerrero, Carlos Aliaga, et al. · Journal of Clinical Oncology
Real World Data of Cyclin-dependent Kinase 4/6 Inhibitors in a European and Latin-american Luminal Advanced Breast Cancer Population. Analysis of Two Centers
2019 · Juan Carlos Samamé Pérez-Vargas, Ariadna Gasol Cudós, et al. · The Breast
Works count: 8
Citation count: 14
H-index: 2
I10-index:
Year
Topic
Type